Izotropic Corporation | Alexander Tokman Joins Izotropic Board of Directors

Alexander Tokman Joins Izotropic Board of Directors


VANCOUVER, BC – November 11, 2022 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, announces that Advisor Mr. Alexander Tokman has joined the Company’s Board of Directors.

Strengthening the Board of Directors with strategic and well-connected industry executives is pertinent to effectively implementing the Company's short and long-term milestone plans, including the intention to up-list to the Nasdaq in due course.

Mr. Tokman is a growth-driven executive leader with over 22 years of global, cross-functional profit and loss leadership, specializing in creating and commercializing new technology businesses in the Healthcare, Consumer Electronics, Semiconductor and AI sectors for Fortune 100, technology Micro-Cap and Start-Up companies. His extensive experience includes leading several global business units within GE Healthcare, where he led the creation, commercialization, and growth of several new global medical imaging businesses, including PET/CT and Molecular Imaging, as well as growing more established modalities such as X-Ray and Mammography. Mr. Tokman also serves as an independent board director on a Nasdaq traded biotech company and the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for diseases diagnosis.

As an Advisor to the Company since 2020, Mr. Tokman has contributed by making key introductions and providing important advice on the development, manufacturing, and marketing aspects of operations.

Izotropic is nearing the completion and unveiling of the first IzoView commercial prototype and subsequent clinical study for market authorization in the USA, and will continue to align with specialized executives and operational personnel on its path to revolutionizing the breast imaging industry with Breast CT technology.

Dr. John McGraw

Investor Relations Contact:
James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1

Media Inquiries Contact:
Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3

About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications, including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks including those related to capital requirements, and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.